中重度溃疡性结肠炎住院期间及出院后激素管理与出院计划的适宜管理建议:RAND适宜性小组结果
该RAND适宜性小组通过文献回顾与两轮匿名投票,针对中重度溃疡性结肠炎住院患者的激素剂量、出院标准、随访及出院后生物制剂或小分子药物启动提出适宜性建议,涵盖静脉甲泼尼龙40-60 mg每24小时或氢化可的松100 mg每日3次、直肠出血缓解和/或排便频率恢复基线后可出院、出院后2周内临床随访及4-6个月内结肠镜检查等。
要点
- 住院期适宜静脉甲泼尼龙40-60 mg每24小时或氢化可的松100 mg每日3次;不耐受高剂量者可用甲泼尼龙40 mg。
- 直肠出血缓解(Mayo亚评分0-1)和/或排便频率恢复基线频率与性状(Mayo亚评分0-1)后可出院。
- 出院后2周内临床随访,4-6个月内行结肠镜检查。
核心结论
- 该小组针对中重度溃疡性结肠炎住院患者的住院期与出院后管理提供了适宜性建议。
研究设计与样本
- 采用RAND适宜性方法,通过文献回顾支持小组投票,投票在主持的虚拟会议前后两轮匿名进行。
主要发现
- 静脉甲泼尼龙40-60 mg每24小时或氢化可的松100 mg每日3次为住院管理适宜方案,不耐受更高剂量时甲泼尼龙40 mg为适宜。
- 直肠出血缓解(Mayo亚评分0-1)和/或排便频率恢复基线频率与性状(Mayo亚评分0-1)时出院为适宜。
- 出院前在医院观察24小时以确保稳定后带泼尼松40 mg出院为适宜。
- 出院时未启动住院期生物制剂或小分子治疗的患者,抗TNF初治者出院后启动抗TNF治疗为适宜。
- 抗TNF经治者,所有患者启动维得利珠单抗或乌司奴单抗、低不良事件风险者启动托法替布为适宜。
关键数值与推荐
- 住院期适宜:静脉甲泼尼龙40-60 mg每24小时或氢化可的松100 mg每日3次;不耐受更高剂量时甲泼尼龙40 mg。
- 出院适宜:直肠出血缓解(Mayo亚评分0-1)和/或排便频率恢复基线频率与性状(Mayo亚评分0-1)。
- 带泼尼松40 mg出院前需在医院观察24小时以确保稳定。
- 抗TNF初治者出院后启动抗TNF治疗为适宜;抗TNF经治者所有患者启动维得利珠单抗或乌司奴单抗、低不良事件风险者启动托法替布为适宜。
- 出院后2周内临床随访、4-6个月内下消化道内镜检查为适宜。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Limited guidance exists for the postdischarge care of patients with ulcerative colitis hospitalized for moderate-severe flares. METHODS: RAND methodology was used to establish appropriateness of inpatient and postdischarge steroid dosing, discharge criteria, follow-up, and postdischarge biologic or small molecule initiation. A literature review informed on the panel's voting, which occurred anonymously during 2 rounds before and after a moderated virtual session. RESULTS: Methylprednisolone 40-60 mg intravenous every 24 hours or hydrocortisone 100 mg intravenous 3 times daily is appropriate for inpatient management, with methylprednisolone 40 mg being appropriate if intolerant of higher doses. It is appropriate to discharge patients once rectal bleeding has resolved (Mayo subscore 0-1) and/or stool frequency has returned to baseline frequency and form (Mayo subscore 0-1). It is appropriate to discharge patients on 40 mg of prednisone after observing patients for 24 hours in hospital to ensure stability before discharge. For patients being discharged on steroids without in-hospital biologic or small molecule therapy initiation, it is appropriate to start antitumor necrosis factor (TNF) therapy after discharge for anti-TNF-naive patients. For anti-TNF-exposed patients, it is appropriate to start vedolizumab or ustekinumab for all patients and tofacitinib for those with a low risk of adverse events. It is appropriate to follow up patients clinically within 2 weeks and with lower endoscopy within 4-6 months after discharge. DISCUSSION: We provide recommendations on the inpatient and postdischarge management of patients with ulcerative colitis hospitalized for moderate-severe flares.
引用
- Dulai PS, Rai V, Raffals LE, et al. Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel. Am J Gastroenterol. 2022. PMID: 35416799. doi:10.14309/ajg.0000000000001775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。